- 51-200 Employees
- Based in New York City, New York
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Most Recent Annual Report
2020 Annual Report and Form 10K
Report Locked. Immunovant, Inc. has reached its limit for free report views.